Results 121 to 130 of about 98,224 (178)

Concurrent Ocular and Dermatologic Toxicities Associated With Docetaxel Chemotherapy. [PDF]

J Adv Pract Oncol
Wittig JA, Grabowski J, Villani SC, Kono SA, Friedrich TJ.   +4 more
europepmc   +1 more source

Pure Red Cell Aplasia Following Neoadjuvant Docetaxel/Carboplatin/Trastuzumab (TCbH) in a 45‑Year‑Old Woman With Breast Cancer Successfully Treated With Cyclosporine. [PDF]

Am J Case Rep
Chen Y, Chen F, Luo R, Ye X.
europepmc   +1 more source

Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial. [PDF]

Breast
Penault-Llorca F, Lusque A, Filleron T, Tran K, Du L, Baehner R, Dalenc F, Lacroix-Triki M, Bachelot T, Andre F, Boucher P, Lemonnier J, Symmans WF.   +12 more
europepmc   +1 more source

Corrigendum to "Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma" [Pharmaceut. Sci. Adv. 2 (2024) 100046]. [PDF]

Pharm Sci Adv
Yao Y, Hu Y, Meng X, Feng F, Xu F, Wang G, Yu H, Li J.   +7 more
europepmc   +1 more source

Excessive Tearing and Lacrimal and Canalicular Blockage Secondary to Docetaxel in Breast Cancer Patients in the Metastatic and Adjuvant Settings. [PDF]

Curr Oncol
Pfeiffer ML, Esmaeli B.
europepmc   +1 more source

Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRAS^G12C mutations. [PDF]

Future Oncol
Barlesi F, Yao W, Duruisseaux M, Doucet L, Azkárate Martínez A, Gregorc V, Juan-Vidal O, Lu S, De Bondt C, de Marinis F, Linardou H, Kim YC, Jotte R, Felip E, Lo Russo G, Reck M, MichenzIe MF, Yang W, Meade JN, Korytowsky B, Mok TSK, KRYSTAL-12 Investigators.   +21 more
europepmc   +1 more source

Dual-mechanism driven adsorption on silica microspheres enables precision pharmacokinetic profiling of liposomal therapeutics. [PDF]

J Pharm Anal
Che J, Zhang Y, Yuan M, Bai Q.
europepmc   +1 more source

Sequential Enzalutamide-Docetaxel Versus Abiraterone-Docetaxel Therapy in Castration-Resistant Prostate Cancer: A Subanalysis of the ENABLE Study. [PDF]

Int J Urol
Kamiyama M, Izumi K, Mitsui T, Shima T, Kato Y, Mita K, Okamura T, Inoue S, Hoshi S, Tanaka N, Yoshio Y, Tatarano S, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Mizokami A.   +18 more
europepmc   +1 more source

AGE-related efficacy and safety of darolutamide triplet therapy in metastatic hormone-sensitive prostate cancer: are we ready for routine clinical practice? [PDF]

Front Oncol
Munoz F, Fiorica F.
europepmc   +1 more source